News/Blog
Read about our latest news:
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
ENB-003 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) Encouraging results support further...
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated Promising preliminary efficacy signals with 33% disease control...
ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
Friday, November 4, 2022 7:00 AM ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company pioneering a...
ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB Therapeutics,...
ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / February 1, 2021...
Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing...
ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab
Monday, June 15, 2020 3:45 PMENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company pioneering a...
IND approval received for lead product ENB-003
January 17, 2020 ENB Therapeutics receives IND approval from the FDA for our Phase 1/2 trial evaluating the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. This is a major milestone for ENB and allows our clinical trial to be initiated...
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors
New York, NY., February 4th, 2019 -- ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD...
ENB Therapeutics Closes Series A Round of Funding
New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the...